Catherine Madigan - 01 Mar 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Medical Officer
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Issuer symbol
SNDX
Transactions as of
01 Mar 2022
Net transactions value
+$2,890,800
Form type
4
Filing time
03 Mar 2022, 15:24:05 UTC
Next filing
03 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Award $2,890,800 +180,000 $16.06 180,000 01 Mar 2022 Common Stock 180,000 $16.06 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty five percent (25%) of the total number of shares underlying the option shall vest on March 1, 2023, and one-thirty-sixth (1/36th) of the remaining shares underlying the option shall vest monthly thereafter on the last day of each month, subject to the reporting person's continuous service on the relevant vesting dates.